ArticleWorld journal of hepatology2025
MANPOWER study: Real-world post-hoc analysis assessing essential phospholipids for non-alcoholic fatty liver disease from the Russian registry.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Essential phospholipids and enzyme-based staging in nonalcoholic fatty liver disease: A call to action.World journal of hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince non-alcoholic fatty liver disease (NAFLD) is associated with abnormal liver function tests, treatment recommendations aim to reduce the level of known markers of liver inflammation, such as alanine transaminase (ALT), aspartate transaminase (AST) and gamma-glutamyl transferase (GGT). Essential phospholipids (EPLs) have been shown to reduce levels of these liver enzymes and improve ultrasonographic features. While non-invasive diagnostic tests have been developed to stage inflammation, these tests were not specifically designed to evaluate patients with NAFLD. This highlights the need to describe the liver enzyme profile across the different levels of NAFLD severity for improved grading and staging of NAFLD.
aimTo describe liver enzyme profiles across NAFLD severity to inform a diagnostic staging algorithm and identify who may benefit from EPLs.
methodsThis post-hoc analysis of the observational MANPOWER study included 2843 adult patients with newly diagnosed NAFLD. The primary endpoint was assessment of baseline liver enzyme profiles. Secondary endpoints were effectiveness of Essentiale
resultsOf the 2843 patients included in this post-hoc analysis, most were female (62.2%), with a mean age of 48.4 years (SD 8.59 years). Overall, mean levels of ALT, AST and GGT increased with NAFLD severity for all three subgroups, with the rate of chronic comorbidities correlated with NAFLD severity. Across each subgroup of interest, Essentiale significantly reduced average liver enzyme levels and improved ultrasonography features, including diffuse liver hyperechogenicity and heterogeneous liver structure (
conclusionLiver enzyme profiles may identify NAFLD severity and allow monitoring of therapeutic response. Essentiale may improve liver enzyme levels and ultrasonography features. An algorithm could aid in the diagnosis/staging of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.